<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03665129</url>
  </required_header>
  <id_info>
    <org_study_id>IPH5401-101</org_study_id>
    <nct_id>NCT03665129</nct_id>
  </id_info>
  <brief_title>IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors</brief_title>
  <acronym>STELLAR-001</acronym>
  <official_title>A Phase I Study of the Anti-C5aR, IPH5401, in Combination With the Anti-PD-L1, Durvalumab, in Patients With Selected Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innate Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Innate Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, dose-escalation and dose-expansion study to evaluate the
      safety, tolerability, antitumor activity of IPH5401 (anti C5aR) in combination with
      Durvalumab (MEDI4736) in Adult Subjects with selected advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2018</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Drug Limited Toxicities (DLTs)</measure>
    <time_frame>From Time of First dose assessed up to 6 weeks</time_frame>
    <description>To assess the occurrence of Drug Limited Toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>From screening visit up to 30 days after the last dose of study medication</time_frame>
    <description>To evaluate the safety profile</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Rate of patients in complete or partial response according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>2 years and 9 months</time_frame>
    <description>duration between the complete or partial response and the first documented progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>2 years and 9 months</time_frame>
    <description>time between the start of treatment and the first documented progression or death</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IPH5401 at different doses and schedule + Durvalumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort expansion NSCLC anti-PD-(L)1 pretreated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IPH5401 at recommended dose and schedule + Durvalumab in NSCLC anti-PD-(L)1 pretreated patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort expansion HCC anti-PD-(L)1 naive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IPH5401 at recommended dose and schedule + Durvalumab in HCC anti-PD-(L)1 naive patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort expansion HCC anti-PD-(L)1 pretreated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IPH5401 at recommended dose and schedule + Durvalumab in HCC anti-PD-(L)1 pretreated patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IPH5401 and Durvalumab</intervention_name>
    <description>IPH5401 and durvalumab</description>
    <arm_group_label>Cohort expansion HCC anti-PD-(L)1 naive</arm_group_label>
    <arm_group_label>Cohort expansion HCC anti-PD-(L)1 pretreated</arm_group_label>
    <arm_group_label>Cohort expansion NSCLC anti-PD-(L)1 pretreated</arm_group_label>
    <arm_group_label>Dose escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with advanced and/or metastatic histologically solid tumors with evidence of
             active disease, who have been treated with a minimum of one line of systemic therapy
             in the metastatic setting, and in expansion part, no more than two prior systemic
             therapies.

          2. At least 18 years of age.

          3. ECOG performance status of ≤1.

          4. Adequate organ function

        Exclusion Criteria:

          1. For patients with Non Small Cell Lung Cancer (NSCLC):

             a. Known actionnable mutation or rearrangement (including but not limited to the
             epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) gene
             rearrangements, ROS-1 alterations or BRAF mutations)

          2. For patient with Hepatocellular carcinoma (HCC):

               1. Hepatic encephalopathy in the past 12 months.

               2. Ascites that requires repeated paracentesis in the past 2 months.

               3. Main portal vein thrombosis.

               4. Active or prior history of gastrointestinal bleeding in the past 12 months.

               5. Prior hepatic transplantation.

          3. Patients with known spinal cord compression.

          4. Symptomatic, untreated, or actively progressing central nervous system (CNS)
             metastases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emmanuel MITRY, MD;PhD</last_name>
    <phone>+33430303030</phone>
    <email>Emmanuel.MITRY@innate-pharma.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Delphine Marie</last_name>
    <email>Delphine.Marie@innate-pharma.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek Sharma, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Frauenshuh Cancer Center</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dylan Zylla, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna C Bendell, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Tolcher, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois Ghiringhelli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Cassier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone- AP-HM</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice Barlesi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego Tosi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire- Hôpital Nord Laennec</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaafar Bennouna, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Edeline, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Massard, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 1, 2018</study_first_submitted>
  <study_first_submitted_qc>September 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2018</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

